Comparative Pharmacology
Head-to-head clinical analysis: MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus TRICHLORMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus TRICHLORMETHIAZIDE.
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs TRICHLORMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moexipril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing diuresis and reducing plasma volume.
Inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water.
One tablet (7.5 mg moexipril / 12.5 mg hydrochlorothiazide or 15 mg moexipril / 25 mg hydrochlorothiazide) orally once daily.
2-4 mg orally once daily; maximum 4 mg/day.
None Documented
None Documented
Moexiprilat (active metabolite) terminal half-life is approximately 2–9 hours (mean ~9 hours in hypertension; prolonged in renal impairment). Hydrochlorothiazide terminal half-life is 6–15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: Twice-daily dosing may be needed for 24-hour BP control; renal impairment requires dose adjustment.
Clinical Note
moderateTrichlormethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin."
Clinical Note
moderateTrichlormethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin."
Clinical Note
moderateTrichlormethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life is approximately 2-6 hours (average 3.5 h); clinical context: short half-life necessitates once or twice daily dosing for sustained diuresis.
Moexipril is eliminated primarily by renal excretion (about 50% as unchanged drug and metabolites) and biliary/fecal excretion (about 50%). Hydrochlorothiazide is eliminated largely unchanged by renal excretion (≥95% via glomerular filtration and tubular secretion).
Primarily renal (tubular secretion); ~70% excreted unchanged in urine; minor biliary/fecal (<10% total).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic
Trichlormethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin."